AIDS

1. FREITAS C, Cooper CL, Kroch AE, Buchan SA, et al
   SARS-CoV-2 breakthrough infection among people with and without HIV in Ontario, Canada.
   AIDS. 2026;40:119-122.
   

   >> Share

   
   

   
   Ann Intern Med

2. TERAN-PLASENCIA JM, Kalil AC
   In adults hospitalized with acute HF, predischarge influenza vaccination reduced a composite of mortality or readmission at 1 y.
   Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-04799.
   

   >> Share

   
   
3. TONG SYC, Gibney KB
   In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia.
   Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-05209.
   

   >> Share

   
   
4. SACKS HS
   In older adults, RSV prefusion F vaccine reduced hospitalization for RSV-related respiratory tract disease vs. no vaccine.
   Ann Intern Med. 2026 Jan 6. doi: 10.7326/ANNALS-25-05113.
   

   >> Share

   
   

   
   Arch Virol

5. ZHANG J, Sun X, Koro C, Fang Y, et al
   Prevalence of group A rotavirus G and P genotypes in children with acute gastroenteritis in China from 2020 to 2021.
   Arch Virol. 2026;171:47.
   

   >> Share

   
   
6. DE OLIVEIRA BARBOSA A, Gava D, Bastos APA, de Lima M, et al
   Immunogenicity of an inactivated vaccine against senecavirus a and duration of the immune response in pigs.
   Arch Virol. 2026;171:33.
   

   >> Share

   
   

   
   BMJ

7. TANNE JH
   RFK slashes US vaccines for children as medical groups threaten legal action.
   BMJ. 2026;392:s34.
   

   >> Share

   
   
8. LANG K
   Is the chickenpox vaccine safe, and why is it now being offered to UK children?
   BMJ. 2026;392:s16.
   

   >> Share

   
   

   
   Clin Infect Dis

9. PURPURA L, Heisler T, Palmer S, Shah J, et al
   Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers.
   Clin Infect Dis. 2026 Jan 9:ciaf624. doi: 10.1093.
   

   >> Share

   
   

   
   Indian Pediatr

10. SINGH A
    Vaccine Nation: How Immunization Shaped India : Ameer Shahul, Pan Macmillian India, Pages 478, Price Rs. 699/.
    Indian Pediatr. 2026 Jan 7. doi: 10.1007/s13312-025-00247.
    

    >> Share

    
    

    
    Infect Immun

11. MASTROENI P, Rossi O, Micoli F
    Multivalent vaccines for invasive Salmonella disease: need, rationale, and immunological foundations.
    Infect Immun. 2026 Jan 6:e0011825. doi: 10.1128/iai.00118.
    

    >> Share

    
    

    
    J Infect

12. AWAN UA, Zafar N, Khan SN, Ahmed N, et al
    Low HPV vaccination coverage in Pakistan: when misinformation undermines infectious disease prevention.
    J Infect. 2026 Jan 2:106674. doi: 10.1016/j.jinf.2025.106674.
    

    >> Share

    
    
13. NESAMAR R, Crowther C, Chiveto DT, Pillay T, et al
    Humoral and cellular immunogenicity of COVID-19 vaccine boosters in participants with advanced HIV disease.
    J Infect. 2026 Jan 7:106676. doi: 10.1016/j.jinf.2026.106676.
    

    >> Share

    
    

    
    J Infect Dis

14. ASARE EO, Lartey BL, Armah GE, Pitzer VE, et al
    Quantifying the impact of switching from Rotarix to Rotavac rotavirus vaccine in Ghana.
    J Infect Dis. 2026 Jan 7:jiag003. doi: 10.1093.
    

    >> Share

    
    
15. MOSCHETTA N, Criscuolo E, Raccagni AR, Capra N, et al
    A humoral dilemma: reassessing monkeypox virus neutralizing antibodies at more than two years from Mpox or MVA-BN vaccination.
    J Infect Dis. 2026 Jan 6:jiag009. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

16. SIEVERS BL, Hyder S, Chan M, Ly S, et al
    Measles vaccination perceptions and willingness to consider novel vaccination approaches in Cambodia's floating villages.
    J Virol. 2026 Jan 7:e0171825. doi: 10.1128/jvi.01718.
    

    >> Share

    
    

    
    JAMA

17. ANDERER S
    WHO Analysis Finds No Causal Link Between Vaccines and Autism.
    JAMA. 2026 Jan 9. doi: 10.1001/jama.2025.23013.
    

    >> Share

    
    
18. MICHNICK AI, MacDonald SC, Cosgrove A, Adimadhyam S, et al
    Interim Safety of RSVpreF Vaccination During Pregnancy.
    JAMA. 2026 Jan 8:e2523452. doi: 10.1001/jama.2025.23452.
    

    >> Share

    
    
19. PRASAD V, Makary MA
    FDA Labeling Change for mRNA COVID-19 Vaccines-Reply.
    JAMA. 2026 Jan 7. doi: 10.1001/jama.2025.21754.
    

    >> Share

    
    
20. MEYEROWITZ EA
    FDA Labeling Change for mRNA COVID-19 Vaccines.
    JAMA. 2026 Jan 7. doi: 10.1001/jama.2025.21752.
    

    >> Share

    
    

    
    Lancet

21. DWEK RA, Feldmann M, Fotinou C, Zitzmann N, et al
    If vaccines falter, broad-spectrum antivirals provide a global shield.
    Lancet. 2026;407:25-26.
    

    >> Share

    
    

    
    MMWR Morb Mortal Wkly Rep

22. AMIN AB, Collins JP, Dong X, Leidner AJ, et al
    Use of the GSK MenACWY-CRM/MenB-4C Pentavalent Meningococcal Vaccine Among Persons Aged >/=10 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2025.
    MMWR Morb Mortal Wkly Rep. 2026;75:7-14.
    

    >> Share

    
    

    
    Nat Immunol

23. FANG C, Esposito M, Hars U, Byrne RT, et al
    Targeting autocrine retinoic acid signaling by ALDH1A2 inhibition enhances antitumor dendritic cell vaccine efficacy.
    Nat Immunol. 2026 Jan 5. doi: 10.1038/s41590-025-02376.
    

    >> Share

    
    

    
    Nat Med

24. KAPULU MC, Orenge F, Kimani D, Kibwana E, et al
    Malaria vaccine protection against intradermal or venous parasites: a randomized phase 2b human challenge trial.
    Nat Med. 2026 Jan 6. doi: 10.1038/s41591-025-04107.
    

    >> Share

    
    
25. RASMUSSEN AL
    US vaccine policy must put America first.
    Nat Med. 2026 Jan 9. doi: 10.1038/d41591-026-00002.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

26. IZU A, Koen A, Jose L, Cutland C, et al
    Persistence of Antibodies at Three, Four and Five Years of Age to Ten-valent Pneumococcal Polysaccharide Protein D-conjugate Vaccine in South African Children According to HIV Status.
    Pediatr Infect Dis J. 2026;45:173-180.
    

    >> Share

    
    
27. LI X, Wang W, Kang X, Hu P, et al
    Vaccine Effectiveness and Clinical Characteristics of Breakthrough Varicella During Outbreaks Among Students in Qingdao, China.
    Pediatr Infect Dis J. 2026 Jan 7. doi: 10.1097/INF.0000000000005133.
    

    >> Share

    
    

    
    Pediatrics

28. HAYEK H, Noble EK, Stewart LS, Sahni LC, et al
    Influenza Vaccine Effectiveness Among Children With and Without Underlying Conditions.
    Pediatrics. 2026 Jan 9:e2025072184. doi: 10.1542/peds.2025-072184.
    

    >> Share

    
    

    
    PLoS One

29. ABDELHAMED H, Riman MM, Arick MA 2nd, Dawood AS, et al
    Investigation mechanisms of action and resistance of Edwardsiella ictaluri to trans-cinnamaldehyde.
    PLoS One. 2026;21:e0340053.
    

    >> Share

    
    

    
    Vaccine

30. GIDUTHURI JG, Vengiau G, Vutliu V, Manineng C, et al
    Behavioural and social drivers of COVID-19 vaccination in Papua New Guinea: A cross-sectional study.
    Vaccine. 2026;74:128207.
    

    >> Share

    
    
31. KATSUTA T, Sato S, Kawazoe Y, Fukuda H, et al
    Active vaccine safety monitoring system using health insurance claims data in Japan: The Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study.
    Vaccine. 2026;74:128209.
    

    >> Share

    
    
32. ZHU Z, Chen Z, Gao Y, Xie Z, et al
    Genetic distance predicts neutralizing antibody titers for monovalent and bivalent SARS-CoV-2 vaccines.
    Vaccine. 2026;73:128185.
    

    >> Share

    
    
33. YE G, Qu C, Liao Z, Wu R, et al
    Engineered flagellin-based adjuvant boosts mucosal immunity in recombinant RSV vaccine.
    Vaccine. 2026;73:128190.
    

    >> Share

    
    
34. CORREIRA JW, Morrison KT, Doll MK
    Homeschooling trends before and after the New York state repeal of nonmedical vaccine exemptions.
    Vaccine. 2026;73:128169.
    

    >> Share

    
    
35. ORELLANA-MANZANO A, Garcia-Angulo A, Quinto F, Munizaga MG, et al
    COVID-19 vaccination campaign, knowledge, and trust in Duran, Ecuador: a cross-sectional study.
    Vaccine. 2026;72:127867.
    

    >> Share

    
    
36. MARTINEZ-DE-ALBENIZ I, Bottomley C, Lucinde R, Kaniu MW, et al
    Determining the dose-response relationship for pneumococcal conjugate vaccines: a nested analysis of the fractional dose PCV trial.
    Vaccine. 2026;73:128186.
    

    >> Share

    
    
37. ZHANG M, Huang S, Ruan C, Jiang Y, et al
    Anti-vaccination attitudes and behavioral intentions towards three recommended vaccinations among Chinese older adults with chronic diseases: A multicenter cross-sectional study.
    Vaccine. 2026;74:128191.
    

    >> Share

    
    
38. YAO X, Su D, Ma Z, Jin Z, et al
    Adjuvant comprising nano-aluminum hydroxide pickering emulsion with polysialic acid for enhanced vaccination.
    Vaccine. 2026;74:128188.
    

    >> Share

    
    
39. DE BRABANDERE L, Herzog SA, Desombere I, Arien KK, et al
    Enhanced immune responses to mRNA compared with adenoviral vector COVID-19 vaccines during pregnancy: implications for pandemic preparedness.
    Vaccine. 2026;73:128153.
    

    >> Share

    
    
40. EDOKA I, Silal S, Jamieson L, Meyer-Rath G, et al
    Corrigendum to "A cost-effectiveness analysis of South Africa's COVID-19 vaccination programme" [Vaccine 42(20) (2024) 125988.
    Vaccine. 2026;74:128162.
    

    >> Share

    
    
41. WILLEMIN T, Guinchard F, Marmey J, Chareyre A, et al
    Comprehensive characterization of multivalent mRNA vaccines functionality by flow cytometry and mass spectrometry.
    Vaccine. 2026;74:128180.
    

    >> Share

    
    
42. LISTER H, Farquharson K, Seale H, Smith LE, et al
    A systematic review of the impact of vaccine reactogenicity on willingness to accept influenza vaccination in adults.
    Vaccine. 2026;74:128195.
    

    >> Share

    
    
43. RENNER TM, Agbayani G, Azizi H, Deschatelets L, et al
    Heterologous vs. homologous vaccine regimens: Sulfated lactosyl archaeol (SLA) archaeosome-adjuvanted SARS-CoV-2 spike protein boost following an mRNA/LNP prime induces robust and balanced immune responses.
    Vaccine. 2026;74:128182.
    

    >> Share

    
    
44. GRANADE C, Lindley M, Nelson J, Asif A, et al
    Bridging the gap: a review of the factors contributing to differences in vaccination coverage among rural and urban adults.
    Vaccine. 2026;74:128148.
    

    >> Share

    
    
45. ALBY-LAURENT F, Ouedrani A, Jateau P, Strullu M, et al
    Safety and immunogenicity of BNT162b2 vaccine in children with acute leukaemia: results and perspectives of an open-label, two-centre, phase 1/2 trial with dose finding study.
    Vaccine. 2026 Jan 7:128130. doi: 10.1016/j.vaccine.2025.128130.
    

    >> Share

    
    
46. LEE SE, Najjengo M, Shaum A, Sekiziyivu AB, et al
    Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to standard dose in children 9-23 months old in Uganda, 2019-2022 - final report.
    Vaccine. 2026;74:128131.
    

    >> Share

    
    
47. QIAO X, Du L, Qin Z, Zhang Y, et al
    Robust immunoreaction induced by a subunit vaccine of PEDV spike protein based on GEM surface-display system.
    Vaccine. 2026;74:128204.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share